From Genotype to Outcomes: RenasightIQ Real-World Evidence in Glomerular Diseases

• This presentation highlights real-world evidence from RenasightIQ to demonstrate how integrated clinical and genetic data are transforming risk stratification and treatment optimization in glomerular disease
• With focused insights from genetic ancestry, we will examine how genetic drivers influence disease trajectory and therapeutic response
• The session will also review real-world treatment effects of steroids/immunosuppression, ACE inhibitors/ARBs, and SGLT2 inhibitors
• Together, these findings underscore how precision medicine approaches can improve prognostic clarity, guide treatment decisions, and drive better patient outcomes

Speakers:

Dinah Clark

Medical Affairs, Biopharma Partnering

Natera

Ronen Schneider

MD, Medical Director, Renal Genetics

Natera